Skip to content

Supplier News

Aurobindo cleared to market Xanax generic

Aurobindo cleared to market Xanax generic

Aurobindo Pharma Ltd. has gained Food and Drug Administration approval for alprazolam tablets, a medication for anxiety. Aurobindo said its alprazolam product — available in dosages of 0.25 mg, 0.5 mg, 1 mg and 2 mg — is a generic version of Xanax tablets from Pfizer Inc. Part of a group of

DenTek launches e-commerce website

DenTek launches e-commerce website

DenTek has gone live with a new branded website featuring full e-commerce capabilities. The oral care brand said Monday that DenTek.com now provides oral care product information and tips plus the ability for consumers to buy items directly through the site.

Pfizer to buy U.S. rights for potential MS generic drug

Pfizer to buy U.S. rights for potential MS generic drug

Pfizer Inc. has entered into an agreement with Synthon to acquire the exclusive U.S. commercialization rights for glatiramer acetate, a potential generic version of Teva Pharmaceuticals’ Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS).

Hikma to buy Roxane for $2.65 billion

Hikma to buy Roxane for $2.65 billion

Hikma Pharmaceuticals PLC, a fast growing multinational pharmaceutical group, plans to acquire Roxane Laboratories from Boehringer Ingelheim in a deal valued at $2.65 billion. Hikma said the agreement stands to transform its position in the U.S.

P&G names Taylor as next CEO

P&G names Taylor as next CEO

David Taylor, Procter & Gamble Co.’s group president of global beauty, grooming and health care, has been chosen to succeed A.G. Lafley as the company’s president and chief executive officer. P&G said late Tuesday that Taylor is slated to take the helm as CEO on Nov.

Sandoz releases Pulmicort Respules generic

Sandoz has launched budesonide inhalation suspension, an asthma medication, in the U.S. market. The Novartis subsidiary said Tuesday that it will market its budesonide inhalation suspension in 1-mg strength, and it expects 180-day generic drug marketing exclusivity for that dosage.

Teva to buy Allergan Generics for $40.5 billion

Teva to buy Allergan Generics for $40.5 billion

Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.

Performance Health launches Atomic Heat

Performance Health launches Atomic Heat

Performance Health LLC has expanded its roster of topical analgesic, rehabilitation and wellness products with Perform Atomic Heat, a new topical formula for warming the body before physical activity and relieving muscle, joint and arthritis pain.

Lupin to acquire Gavis Pharmaceuticals

Lupin to acquire Gavis Pharmaceuticals

Lupin Ltd. plans to buy Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal. Lupin said Thursday that the acquisition will boost its scale in the U.S.

Markwins names Rogers as Physicians Formula president

Jeff Rogers has been appointed as president of the Physicians Formula Group at Markwins International Corp. Rogers takes over from Ingrid Jackel, who left the company to join natural beauty care manufacturer Yes To Inc. as chief executive officer.